CN106536509B - 作为组蛋白甲基转移酶和dna甲基转移酶的双重抑制剂的新型化合物 - Google Patents

作为组蛋白甲基转移酶和dna甲基转移酶的双重抑制剂的新型化合物 Download PDF

Info

Publication number
CN106536509B
CN106536509B CN201580034131.4A CN201580034131A CN106536509B CN 106536509 B CN106536509 B CN 106536509B CN 201580034131 A CN201580034131 A CN 201580034131A CN 106536509 B CN106536509 B CN 106536509B
Authority
CN
China
Prior art keywords
compound
formula
cancer
mmol
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580034131.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106536509A (zh
Inventor
X·阿吉雷·埃娜
J·奥亚扎巴尔·圣玛丽娜
F·普罗斯佩尔·卡多索
M·O·拉巴尔·格雷西亚
J·R·罗德里格斯·马多
E·圣·乔斯·埃内里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacion para la Investigacion Medica Aplicada
Original Assignee
Fundacion para la Investigacion Medica Aplicada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion para la Investigacion Medica Aplicada filed Critical Fundacion para la Investigacion Medica Aplicada
Publication of CN106536509A publication Critical patent/CN106536509A/zh
Application granted granted Critical
Publication of CN106536509B publication Critical patent/CN106536509B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201580034131.4A 2014-06-16 2015-03-30 作为组蛋白甲基转移酶和dna甲基转移酶的双重抑制剂的新型化合物 Active CN106536509B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382230.2 2014-06-16
EP14382230 2014-06-16
PCT/EP2015/056860 WO2015192981A1 (en) 2014-06-16 2015-03-30 Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases

Publications (2)

Publication Number Publication Date
CN106536509A CN106536509A (zh) 2017-03-22
CN106536509B true CN106536509B (zh) 2020-06-09

Family

ID=51136403

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580034131.4A Active CN106536509B (zh) 2014-06-16 2015-03-30 作为组蛋白甲基转移酶和dna甲基转移酶的双重抑制剂的新型化合物

Country Status (9)

Country Link
US (1) US9840500B2 (https=)
EP (1) EP3154957B1 (https=)
JP (1) JP6527534B2 (https=)
CN (1) CN106536509B (https=)
AU (1) AU2015276537B2 (https=)
CA (1) CA2987978C (https=)
DK (1) DK3154957T3 (https=)
ES (1) ES2769648T3 (https=)
WO (1) WO2015192981A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501904A (ja) * 2015-12-14 2019-01-24 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ Ｄｎａメチルトランスフェラーゼの阻害剤としての２，４，６，７−四置換キノリン化合物
HUE064145T2 (hu) * 2016-04-15 2024-03-28 Epizyme Inc Amin-szubsztituált aril- vagy heteroaril vegyületek, mint EHMT1 és EHMT2 inhibitorok
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2017201199A1 (en) * 2016-05-17 2017-11-23 Duke University Compositions and methods for the treatment of prader-willi syndrome
WO2018049000A1 (en) * 2016-09-08 2018-03-15 The General Hospital Corporation Treatment of cancers having alterations within the swi/snf chromatin remodeling complex
WO2018119065A1 (en) 2016-12-22 2018-06-28 Asddr, Llc Use of histone methyltransferase inhibitors and histone deacetylase inhibitors for therapy of phelan-mcdermid syndrome
WO2018119208A1 (en) * 2016-12-22 2018-06-28 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors
EP3600318A4 (en) * 2017-03-31 2021-06-09 Epizyme, Inc. METHOD OF USING EHMT2 INHIBITORS
CN110621316B (zh) 2017-04-21 2024-01-26 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
WO2018226998A1 (en) 2017-06-09 2018-12-13 Global Blood Therapeutics, Inc. Azaindole compounds as histone methyltransferase inhibitors
WO2018229139A1 (en) 2017-06-14 2018-12-20 Fundación Para La Investigación Médica Aplicada Novel compounds for use in cancer
WO2019036384A1 (en) 2017-08-15 2019-02-21 Global Blood Therapeutics, Inc. TRICYCLIC COMPOUNDS AS HISTONE INHIBITORS METHYLTRANSFERASES
WO2019036377A1 (en) 2017-08-15 2019-02-21 Global Blood Therapeutics, Inc. TRICYCLIC COMPOUNDS AS HISTONE INHIBITORS METHYLTRANSFERASES
CA3079273A1 (en) * 2017-10-18 2019-04-25 Epizyme, Inc. Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof
IL273824B2 (en) * 2017-10-18 2024-07-01 Epizyme Inc Methods for using EHMT2 inhibitors in the treatment or prevention of blood disorders
WO2019229765A1 (en) * 2018-05-29 2019-12-05 Council Of Scientific & Industrial Research, India Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof
WO2019243236A1 (en) 2018-06-18 2019-12-26 Fundación Para La Investigación Médica Aplicada New anticancer drug combinations
CN112390791B (zh) * 2019-08-14 2023-08-01 复旦大学 一类dna甲基转移酶1荧光探针及其用途
CA3189027A1 (en) 2020-07-11 2022-01-20 Pfizer Inc. Antiviral heteroaryl ketone derivatives
CA3188260A1 (en) * 2020-08-07 2022-02-10 Dimitrios Iliopoulos Small molecules for the treatment of autoimmune diseases and cancer
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN115160294B (zh) * 2022-06-27 2023-09-29 中山大学 一种G9a/GLP共价抑制剂及其制备方法及应用
CN120965666B (zh) * 2025-10-21 2026-02-17 四川大学华西医院 一种喹啉类化合物、制备方法和用途及其药物组合物

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001154A1 (en) * 1997-07-03 1999-01-14 University Of Iowa Research Foundation Method for inhibiting immunostimulatory dna associated responses
WO2000076982A1 (en) * 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
CN1290698A (zh) * 1999-10-01 2001-04-11 弗·哈夫曼-拉罗切有限公司 喹啉－4－基衍生物i
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
WO2004056352A1 (en) * 2002-12-19 2004-07-08 Scios, Inc. TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-β INHIBITORS
CN101535295A (zh) * 2006-10-12 2009-09-16 休普基因公司 用于调节dna甲基化的喹啉衍生物
CN101889008A (zh) * 2007-10-12 2010-11-17 休普基因公司 用于调节dna甲基化的喹啉衍生物
CN102596200A (zh) * 2009-11-07 2012-07-18 默克专利有限公司 作为TGF-β受体激酶抑制剂的杂芳基氨基喹啉类
CN102597218A (zh) * 2009-08-12 2012-07-18 国立大学法人京都大学 用于诱导多能干细胞分化成神经前体细胞的方法
WO2013062943A1 (en) * 2011-10-24 2013-05-02 Glaxosmithkline Intellectual Property Development Limited New compounds
WO2013140148A1 (en) * 2012-03-19 2013-09-26 Imperial Innovations Limited Quinazoline compounds and their use in therapy
WO2014072391A1 (en) * 2012-11-09 2014-05-15 St-Ericsson Sa Analog to digital conversion method with offset tracking and correction and analog to digital converter implementing the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1088818T3 (da) * 1999-10-01 2005-03-14 Hoffmann La Roche Quinolin-4-yl-derivater
WO2004112710A2 (en) * 2003-06-17 2004-12-29 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß
EP2174938A1 (en) * 2006-10-12 2010-04-14 SuperGen, Inc. Quinoline derivatives for modulating DNA methylation
CN102625799A (zh) * 2009-06-25 2012-08-01 安姆根有限公司 杂环化合物及其用途
EP2730558A1 (en) 2012-11-08 2014-05-14 Ikerchem, S.L. Indole derivatives, pharmaceutical compositions containing such indoles and their use as DNA methylation modulators
JP6338601B2 (ja) * 2013-03-01 2018-06-06 フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ ホスホジエステラーゼとヒストンデアセチラーゼの二重阻害剤としての新規な化合物

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001154A1 (en) * 1997-07-03 1999-01-14 University Of Iowa Research Foundation Method for inhibiting immunostimulatory dna associated responses
WO2000076982A1 (en) * 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
CN1290698A (zh) * 1999-10-01 2001-04-11 弗·哈夫曼-拉罗切有限公司 喹啉－4－基衍生物i
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
WO2004056352A1 (en) * 2002-12-19 2004-07-08 Scios, Inc. TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-β INHIBITORS
CN101535295A (zh) * 2006-10-12 2009-09-16 休普基因公司 用于调节dna甲基化的喹啉衍生物
CN101889008A (zh) * 2007-10-12 2010-11-17 休普基因公司 用于调节dna甲基化的喹啉衍生物
CN102597218A (zh) * 2009-08-12 2012-07-18 国立大学法人京都大学 用于诱导多能干细胞分化成神经前体细胞的方法
CN102596200A (zh) * 2009-11-07 2012-07-18 默克专利有限公司 作为TGF-β受体激酶抑制剂的杂芳基氨基喹啉类
WO2013062943A1 (en) * 2011-10-24 2013-05-02 Glaxosmithkline Intellectual Property Development Limited New compounds
WO2013140148A1 (en) * 2012-03-19 2013-09-26 Imperial Innovations Limited Quinazoline compounds and their use in therapy
WO2014072391A1 (en) * 2012-11-09 2014-05-15 St-Ericsson Sa Analog to digital conversion method with offset tracking and correction and analog to digital converter implementing the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Antagonism of Immunostimulatory CpG-Oligodeoxynucleotides by Quinacrine, Chloroquine, and Structurally Related Compounds;Donald E. Macfarlane;《The Journal of Immunology》;19981231;第160卷;全文 *
Discovery of a Novel Class of Selective Non-Peptide Antagonists for the Human;Giuseppe A. M. Giardina;《J. Med. Chem.》;19971231;第40卷(第12期);全文 *
Synthetic Antimalarials. The Preparation of Certain 4-Amino quinolines1;By Nathan L. Drake;《J. Am. Chem. Soc.》;19460630;第68卷;全文 *

Also Published As

Publication number Publication date
ES2769648T3 (es) 2020-06-26
US20170121316A1 (en) 2017-05-04
CN106536509A (zh) 2017-03-22
EP3154957A1 (en) 2017-04-19
CA2987978A1 (en) 2015-12-23
JP6527534B2 (ja) 2019-06-05
US9840500B2 (en) 2017-12-12
DK3154957T3 (da) 2020-02-17
JP2017524668A (ja) 2017-08-31
EP3154957B1 (en) 2019-11-20
AU2015276537B2 (en) 2019-03-14
AU2015276537A1 (en) 2017-01-05
WO2015192981A1 (en) 2015-12-23
CA2987978C (en) 2022-08-16

Similar Documents

Publication Publication Date Title
CN106536509B (zh) 作为组蛋白甲基转移酶和dna甲基转移酶的双重抑制剂的新型化合物
JP6754864B2 (ja) Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物
CN115803325B (zh) 一种egfr抑制剂及其制备方法和应用
TWI551595B (zh) 2,4-disubstituted benzene-1,5-diamine derivatives and their use, Its preparation of pharmaceutical compositions and pharmaceutical compositions
CN105899490B (zh) 嘧啶fgfr4抑制剂
CN105315285B (zh) 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
JP6035423B2 (ja) 新規な縮合ピリミジン化合物又はその塩
CN107531683B (zh) Usp7抑制剂化合物及使用方法
TWI669300B (zh) 嘧啶類衍生物、其製備方法、其藥物組合物以及其在醫藥上的用途
JP6795518B2 (ja) キナーゼを阻害する組成物及び方法
CN108431000A (zh) 作为dna甲基转移酶抑制剂的新型化合物
CN108602798A (zh) 作为dna甲基转移酶抑制剂的2,4,6,7-四元取代的喹啉化合物
TW201934546A (zh) 嘧啶類化合物、其製備方法及其醫藥用途
CN107698603A (zh) 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
JP2022547294A (ja) キナーゼ阻害剤としての３，５－ジ置換ピラゾール化合物およびその応用
CN102947302A (zh) 三唑并[4，5-b]吡啶衍生物
CN110343095A (zh) 一类精氨酸甲基转移酶抑制剂及其药物组合物和用途
WO2025180470A1 (zh) 细胞周期蛋白依赖性激酶抑制剂及其医药用途
HK40077297B (zh) 氮杂-喹啉化合物及其用途
HK1248684B (en) Usp7 inhibitor compounds and methods of use
HK1217703B (en) Novel fused pyrimidine compound or salt thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant